Moderna (MRNA) Operating Leases (2018 - 2026)

Moderna (MRNA) has reported Operating Leases for 9 consecutive years, with $659.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases fell 3.37% year-over-year to $659.0 million in Q2 2026; TTM through Jun 2026 was $659.0 million, a 3.37% decrease from a year earlier, with the FY2025 full-year figure at $653.0 million, down 2.68% from the prior year.
• Operating Leases was $659.0 million for Q2 2026 at Moderna, down from $664.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $730.0 million in Q3 2023 and troughed at $92.0 million in Q4 2022.
• A 5-year average of $491.7 million and a median of $660.5 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases fell 13.21% in 2022 and soared 598.91% in 2023, its largest moves.
• Over 5 years, Operating Leases stood at $92.0 million in 2022, then jumped by 598.91% to $643.0 million in 2023, then increased by 4.35% to $671.0 million in 2024, then decreased by 2.68% to $653.0 million in 2025, then increased by 0.92% to $659.0 million in 2026.
• The last three Operating Leases figures came in at $659.0 million (Q2 2026), $664.0 million (Q1 2026), and $653.0 million (Q4 2025), per Business Quant data.